RT Book, Section A1 Jameson, J. Larry A1 Longo, Dan L. A2 Jameson, J. Larry SR Print(0) ID 1141276430 T1 Paraneoplastic Syndromes: Endocrinologic/Hematologic T2 Harrison's Endocrinology, 4e YR 2017 FD 2017 PB McGraw-Hill Education PP New York, NY SN 9781259835728 LK accessbiomedicalscience.mhmedical.com/content.aspx?aid=1141276430 RD 2024/03/28 AB Neoplastic cells can produce a variety of products that can stimulate hormonal, hematologic, dermatologic, and neurologic responses. Paraneoplastic syndromes is the term used to refer to the disorders that accompany benign or malignant tumors but are not directly related to mass effects or invasion. Tumors of neuroendocrine origin, such as small-cell lung carcinoma (SCLC) and carcinoids, produce a wide array of peptide hormones and are common causes of paraneoplastic syndromes. However, almost every type of tumor has the potential to produce hormones or to induce cytokine and immunologic responses. Careful studies of the prevalence of paraneoplastic syndromes indicate that they are more common than is generally appreciated. The signs, symptoms, and metabolic alterations associated with paraneoplastic disorders may be overlooked in the context of a malignancy and its treatment. Consequently, atypical clinical manifestations in a patient with cancer should prompt consideration of a paraneoplastic syndrome. The most common endocrinologic and hematologic syndromes associated with underlying neoplasia will be discussed here.